PERSONALIZED THERAPY OF CHRONIC DAILY HEADACHES: THE IMPORTANCE OF GENETIC AND VASCULAR MARKERS
Vol. 5 No. 8 (2025): Eurasian Journal of Medical and Natural Sciences 56-59
Abstract
This article highlights the significance of a personalized approach in the treatment of chronic daily headaches (CDH). Special attention is given to the role of genetic and vascular markers in the pathogenesis of the disease and the effectiveness of therapy. Genetic factors play a key role in determining the individual characteristics of headaches and in predicting the body’s response to medications. Vascular markers allow the assessment of changes in cerebral circulation and brain trophics. The results of scientific analysis demonstrate that the use of personalized therapy can enhance treatment effectiveness, reduce side effects, and improve patients’ quality of life.
Keywords:
References
Diener HC, Solbach K, Holle D, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016;12(10):575-583.
Jiménez-Sánchez L, et al. Role of homocysteine in migraine: pathways, genes and pharmacogenetics. Pharmacol Res. 2021;167:105576.
Kowa H, et al. The influence of MTHFR gene polymorphism on the efficacy of triptans in migraine attacks. Neurology. 2012;78(7):544-547.
Ke X, et al. The link between hyperhomocysteinemia and vascular cognitive impairment: A meta-analysis. Neurosci Biobehav Rev. 2021;126:146-158.
Bockowski L, Sobaniec W, Kulak W. Plasma homocysteine and B vitamins in children with migraine. Headache. 2005;45(4):346-352.
Downloads
Published
Issue
Section
How to Cite
